Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Operating Leases: 2019-2024

Historic Operating Leases for Editas Medicine (EDIT) over the last 6 years, with Dec 2024 value amounting to $20.4 million.

  • Editas Medicine's Operating Leases fell 38.61% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year decrease of 38.61%. This contributed to the annual value of $20.4 million for FY2024, which is 16.38% down from last year.
  • Per Editas Medicine's latest filing, its Operating Leases stood at $20.4 million for FY2024, which was down 16.38% from $24.4 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Operating Leases peaked at $32.9 million during FY2022, and registered a low of $16.1 million during FY2021.
  • In the last 3 years, Editas Medicine's Operating Leases had a median value of $24.4 million in 2023 and averaged $25.9 million.
  • Per our database at Business Quant, Editas Medicine's Operating Leases spiked by 104.52% in 2022 and then declined by 25.84% in 2023.
  • Over the past 5 years, Editas Medicine's Operating Leases (Yearly) stood at $19.3 million in 2020, then declined by 16.84% to $16.1 million in 2021, then spiked by 104.52% to $32.9 million in 2022, then dropped by 25.84% to $24.4 million in 2023, then declined by 16.38% to $20.4 million in 2024.